| アブストラクト | Prostaglandin F2alpha (PGF2alpha) analog formulations are the most commonly used drugs for glaucoma treatment. They are known to be superior to beta-blockers for reducing intraocular pressure and can be effective all through the day. Because of the action, topical beta-blockers are contraindicated for patients with bronchial asthma. PGF2alpha is also known to act as a constrictor of the respiratory tract. The present study aims to analyze the relationship between PGF2alpha analogs and asthma. In addition, we utilized beta-blockers and combined formulations of both contents to evaluate for comparison with PGF2alpha analogs. Data from Japanese adverse drug event reports (JADERs) from April 2004 to January 2016 were used for analysis. The drugs of interest were 4 PGF2alpha analogs, 4 beta-blockers, and 2 combined formulations of both. For quantitative signal detection, the reporting odds ratios (RORs) with Haldane-Anscombe 1/2 correction were calculated. The corrected RORs (95%CI) were detected to be 4.73 (2.30-9.75) for PGF2alpha analogs, 4.61 (1.82-11.7) for beta-blockers, and 28.7 (12.1-68.1) for combined formulations. Our results suggest that not only topical beta-blockers but also PGF2alpha analogs are associated with asthma, and the combined formulations have stronger associations with asthma than when administered alone. Therefore, further clinical research will be necessary, and careful attention should be paid to any glaucoma patient using PGF2alpha analogs for asthma symptoms. |
|---|
| ジャーナル名 | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan |
|---|
| Pubmed追加日 | 2018/04/03 |
|---|
| 投稿者 | Ohyama, Katsuhiro; Sugiura, Munetoshi |
|---|
| 組織名 | Center for Experiential Pharmacy Practice, School of Pharmacy, Tokyo University;of Pharmacy and Life Science.;Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo;University of Pharmacy and Life Science. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/29608006/ |
|---|
